Oncoceutics featured in Global Pheochromocytoma Pipeline Report 2019: Development Activities & Commercial Assessment
Please find the report here.
As part of an exclusive series spotlighting the inside perspectives of thought leaders on topics shaping the future of new medicines, WuXi AppTec Communications spoke with Schalop about his company’s technology and the challenges of developing new therapies for high-grade glioma patients. The full article can be found here.
AuburnExaminer: Defeat DIPG Executive Director Jenny Mosier Speaks at FDA Public Hearing Regarding ONC201. The full article can be found here.
Oncoceutics, Inc. – Philadelphia-based Oncoceutics, Inc. will showcase data from its ongoing trial assessing ONC201 in adult recurrent H3 K27M-mutant glioma. The oral abstract session presentation, entitled “Single agent ONC201 in adult recurrent H3 K27M-mutant glioma” will describe the clinical experience of ONC201, in adults with recurrent H3 K27M-mutant glioma. ONC201 is an orally active